{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:25:22Z","timestamp":1789097122377,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00277-021-04605-w","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T11:02:45Z","timestamp":1627556565000},"page":"2463-2469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in \u03b2-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype"],"prefix":"10.1007","volume":"100","author":[{"given":"Negin","family":"Shokrgozar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Golmoghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vida","family":"Moayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedigheh","family":"Sharifzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-0979","authenticated-orcid":false,"given":"Nargess","family":"Arandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"issue":"6","key":"4605_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/gim.2016.173","volume":"19","author":"R Origa","year":"2017","unstructured":"Origa R (2017) \u03b2-Thalassemia. Genet Med 19(6):609\u2013619","journal-title":"Genet Med"},{"issue":"1","key":"4605_CR2","doi-asserted-by":"publisher","first-page":"e2017018","DOI":"10.4084\/mjhid.2017.018","volume":"9","author":"V De Sanctis","year":"2017","unstructured":"De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, Daar S, Wali Y, Yassin M, Soliman N (2017) \u03b2-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis 9(1):e2017018","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"4605_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1750-1172-5-11","volume":"5","author":"R Galanello","year":"2010","unstructured":"Galanello R, Origa R (2010) Beta-thalassemia. Orphanet J Rare Dis 5(1):11","journal-title":"Orphanet J Rare Dis"},{"key":"4605_CR4","doi-asserted-by":"crossref","unstructured":"Fibach E, Rachmilewitz EA (2017) Pathophysiology and treatment of patients with beta-thalassemia\u2013an update. F1000Res 6:2156","DOI":"10.12688\/f1000research.12688.1"},{"issue":"17","key":"4605_CR5","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1182\/blood-2018-06-818187","volume":"132","author":"AT Taher","year":"2018","unstructured":"Taher AT, Cappellini MD (2018) How I manage medical complications of \u03b2-thalassemia in adults. Blood 132(17):1781\u20131791","journal-title":"Blood"},{"issue":"2","key":"4605_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.molimm.2015.10.005","volume":"68","author":"JC Tan","year":"2015","unstructured":"Tan JC, Armstrong NJ, Yuan FF, Flower RL, Dyer WB (2015) Identification of genetic polymorphisms that predict responder\/non-responder profiles to the RhD antigen. Mol Immunol 68(2):628\u2013633","journal-title":"Mol Immunol"},{"issue":"5","key":"4605_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2257.2006.00856.x","volume":"29","author":"M Karimi","year":"2007","unstructured":"Karimi M, Nikrooz P, Kashef S, Jamalian N, Davatolhagh Z (2007) RBC alloimmunization in blood transfusion-dependent \u03b2-thalassemia patients in southern Iran. Int J Lab Hematol 29(5):321\u2013326","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"4605_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12185-016-2140-x","volume":"105","author":"AM Zahran","year":"2017","unstructured":"Zahran AM, Saad K, Elsayh KI, Alblihed MA (2017) Characterization of circulating CD4+ CD8+ double positive and CD4\u2212 CD8\u2212 double negative T-lymphocyte in children with \u03b2-thalassemia major. Int J Hematol 105(3):265\u2013271","journal-title":"Int J Hematol"},{"issue":"1","key":"4605_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S (2017) Regulatory T cells in cancer immunotherapy. Cell Res 27(1):109\u2013118","journal-title":"Cell Res"},{"issue":"22","key":"4605_CR10","doi-asserted-by":"publisher","first-page":"5624","DOI":"10.1182\/blood-2008-12-193748","volume":"113","author":"W Bao","year":"2009","unstructured":"Bao W, Yu J, Heck S, Yazdanbakhsh K (2009) Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood 113(22):5624\u20135627","journal-title":"Blood"},{"issue":"18","key":"4605_CR11","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-12-1972","volume":"19","author":"CJ Nirschl","year":"2013","unstructured":"Nirschl CJ, Drake CG (2013) Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 19(18):4917\u20134924","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4605_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44(5):989\u20131004","journal-title":"Immunity"},{"issue":"1","key":"4605_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98","journal-title":"Am J Clin Oncol"},{"key":"4605_CR14","first-page":"29","volume":"410","author":"K Fujio","year":"2017","unstructured":"Fujio K, Yamamoto K, Okamura T (2017) Overview of LAG-3-expressing, IL-10-producing regulatory T cells. Curr Top Microbiol Immunol 410:29\u201345","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7","key":"4605_CR15","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/eji.201344413","volume":"45","author":"ME Turnis","year":"2015","unstructured":"Turnis ME, Andrews LP, Vignali DA (2015) Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol 45(7):1892\u20131905","journal-title":"Eur J Immunol"},{"key":"4605_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jri.2016.10.113","volume":"118","author":"X-H Hu","year":"2016","unstructured":"Hu X-H, Tang M-X, Mor G, Liao A-H (2016) Tim-3: expression on immune cells and roles at the maternal-fetal interface. J Reprod Immunol 118:92\u201399","journal-title":"J Reprod Immunol"},{"issue":"12","key":"4605_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6(12):1245\u20131252","journal-title":"Nat Immunol"},{"key":"4605_CR18","doi-asserted-by":"crossref","unstructured":"Dehghani M, Shokrgozar N, Ramzi M, Kalani M, Golmoghaddam H, Arandi N (2021) The impact of selenium on regulatory T cell frequency and immune checkpoint receptor expression in patients with diffuse large B cell lymphoma (DLBCL). Cancer Immunol Immunother","DOI":"10.1007\/s00262-021-02889-5"},{"key":"4605_CR19","doi-asserted-by":"crossref","unstructured":"Shokrgozar N, Amirian N, Ranjbaran R, Bazrafshan A, Sharifzadeh S (2020) Evaluation of regulatory T cells frequency and FoxP3\/GDF-15 gene expression in \u03b2-thalassemia major patients with and without alloantibody; correlation with serum ferritin and folate levels. Ann Hematol 1\u20139","DOI":"10.1007\/s00277-020-03931-9"},{"key":"4605_CR20","doi-asserted-by":"crossref","unstructured":"Shah FT, Sayani F, Trompeter S, Drasar E, Piga A (2019) Challenges of blood transfusions in \u03b2-thalassemia. Blood Rev 37:100588","DOI":"10.1016\/j.blre.2019.100588"},{"issue":"9","key":"4605_CR21","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1111\/trf.13695","volume":"56","author":"AM Abdelrazik","year":"2016","unstructured":"Abdelrazik AM, Elshafie SM, El Said MN, Ezzat Ahmed GM, Al-Gamil AKA, El Nahhas MGM, Sady AAB (2016) Study of red blood cell alloimmunization risk factors in multiply transfused thalassemia patients: role in improving thalassemia transfusion practice in Fayoum. Egypt Transfusion 56(9):2303\u20132307","journal-title":"Egypt Transfusion"},{"key":"4605_CR22","unstructured":"Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A (2003) Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit 9(1):Ra19\u201322"},{"issue":"6","key":"4605_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1159\/000369079","volume":"41","author":"NA Hanchard","year":"2014","unstructured":"Hanchard NA, Moulds JM, Belmont JW, Chen A (2014) A genome-wide screen for large-effect alloimmunization susceptibility loci among red blood cell transfusion recipients with sickle cell disease. Transfus Med Hemother 41(6):453\u2013461","journal-title":"Transfus Med Hemother"},{"key":"4605_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/asheducation-2016.1.446","volume":"1","author":"JE Hendrickson","year":"2016","unstructured":"Hendrickson JE (2016) Tormey CA (2016) Understanding red blood cell alloimmunization triggers. Hematology Am Soc Hematol Educ Program 1:446\u2013451","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"4605_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/088800102753356194","volume":"19","author":"U Ezer","year":"2002","unstructured":"Ezer U, G\u00fclderen F, Culha VK, Akg\u00fcl N, G\u00fcrb\u00fcz O (2002) Immunological status of thalassemia syndrome. Pediatr Hematol Oncol 19(1):51\u201358","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"4605_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/(SICI)1097-0320(20000215)42:1<11::AID-CYTO3>3.0.CO;2-1","volume":"42","author":"K Pattanapanyasat","year":"2000","unstructured":"Pattanapanyasat K, Thepthai C, Lamchiagdhase P, Lerdwana S, Tachavanich K, Thanomsuk P, Wanachiwanawin W, Fucharoen S, Darden JM (2000) Lymphocyte subsets and specific T-cell immune response in thalassemia. Cytometry 42(1):11\u201317","journal-title":"Cytometry"},{"issue":"1","key":"4605_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00277-008-0564-y","volume":"88","author":"M Gharagozloo","year":"2009","unstructured":"Gharagozloo M, Karimi M, Amirghofran Z (2009) Double-faced cell-mediated immunity in beta-thalassemia major: stimulated phenotype versus suppressed activity. Ann Hematol 88(1):21\u201327","journal-title":"Ann Hematol"},{"issue":"1","key":"4605_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 18(1):155","journal-title":"Mol Cancer"},{"key":"4605_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86","journal-title":"Front Oncol"},{"issue":"7","key":"4605_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10875-019-00684-7","volume":"39","author":"P Georgiev","year":"2019","unstructured":"Georgiev P, Charbonnier L-M, Chatila TA (2019) Regulatory T cells: the many faces of Foxp3. J Clin Immunol 39(7):623\u2013640","journal-title":"J Clin Immunol"},{"issue":"11","key":"4605_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri.2017.75","volume":"17","author":"L Lu","year":"2017","unstructured":"Lu L, Barbi J, Pan F (2017) The regulation of immune tolerance by FOXP3. Nat Rev Immunol 17(11):703","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"4605_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/13543776.2019.1642873","volume":"29","author":"M Perez-Santos","year":"2019","unstructured":"Perez-Santos M, Anaya-Ruiz M, Cebada J, Bandala C, Landeta G, Mart\u00ednez-Morales P, Villa-Ruano N (2019) LAG-3 antagonists by cancer treatment: a patent review. Expert Opin Ther Pat 29(8):643\u2013651","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"4605_CR33","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","volume":"174","author":"CJ Workman","year":"2005","unstructured":"Workman CJ, Vignali DA (2005) Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 174(2):688\u2013695","journal-title":"J Immunol"},{"issue":"4","key":"4605_CR34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","volume":"21","author":"C-T Huang","year":"2004","unstructured":"Huang C-T, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI (2004) Role of LAG-3 in regulatory T cells. Immunity 21(4):503\u2013513","journal-title":"Immunity"},{"issue":"11","key":"4605_CR35","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","volume":"184","author":"C Camisaschi","year":"2010","unstructured":"Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, Parmiani G, Belli F, Rivoltini L, Castelli C (2010) LAG-3 expression defines a subset of CD4+ CD25highFoxp3+ regulatory T cells that are expanded at tumor sites. J Immunol 184(11):6545\u20136551","journal-title":"J Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04605-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04605-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04605-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T08:12:46Z","timestamp":1631607166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04605-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4605"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04605-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]},"assertion":[{"value":"28 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed according to the ethical standards of the local Ethics Committee of Shiraz University of Medical Sciences (ethical code IR.SUMS.REC.1398.1387) and in compliance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}